Chembio Diagnostics
Market Cap
US$94.3m
Last Updated
2019/10/19 23:47 UTC
Data Sources
Company Financials +
Executive Summary
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.
Snowflake
Fundamentals
Mediocre balance sheet and overvalued.
Similar Companies
Share Price & News
How has Chembio Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.2%
CEMI
1.9%
US Medical Equipment
0.4%
US Market
1 Year Return
-44.4%
CEMI
15.6%
US Medical Equipment
6.9%
US Market
Return vs Industry: CEMI underperformed the US Medical Equipment industry which returned 15.6% over the past year.
Return vs Market: CEMI underperformed the US Market which returned 6.9% over the past year.
Shareholder returns
| CEMI | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.2% | 1.9% | 0.4% |
| 30 Day | -23.0% | -1.7% | -1.1% |
| 90 Day | -10.5% | -0.03% | -0.5% |
| 1 Year | -44.4%-44.4% | 16.5%15.6% | 9.3%6.9% |
| 3 Year | -23.3%-23.3% | 72.1%66.9% | 45.8%36.4% |
| 5 Year | 34.6%34.6% | 125.8%100.8% | 62.9%45.1% |
Price Volatility Vs. Market
How volatile is Chembio Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
How Does Investing In Chembio Diagnostics, Inc. (NASDAQ:CEMI) Impact The Volatility Of Your Portfolio?3 weeks ago | Simply Wall St
Why Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) CEO Pay Matters To You1 month ago | Simply Wall St
Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?Valuation
Is Chembio Diagnostics undervalued compared to its fair value and its price relative to the market?
3.38x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CEMI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: CEMI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate CEMI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CEMI is good value based on its PB Ratio (3.4x) compared to the US Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is Chembio Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
77.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CEMI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CEMI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CEMI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CEMI's revenue (17.2% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: CEMI's revenue (17.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if CEMI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Chembio Diagnostics performed over the past 5 years?
-29.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: CEMI is unprofitable, and losses have increased over the past 5 years at a rate of -29.6% per year.
Accelerating Growth: Unable to compare CEMI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CEMI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: CEMI has a negative Return on Equity (-41.12%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: CEMI is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: CEMI is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Chembio Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: CEMI's short term assets ($21.9M) exceeds its short term liabilities ($6.5M)
Long Term Liabilities: CEMI's short term assets (21.9M) exceeds its long term liabilities (7.6M)
Debt to Equity History and Analysis
Debt Level: CEMI's debt to equity ratio (1%) is considered satisfactory
Reducing Debt: Insufficient data to determine if CEMI's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: CEMI has a high level of physical assets or inventory.
Debt Coverage by Assets: CEMI's debt is covered by short term assets (assets are 76.139050x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CEMI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CEMI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -49.7% each year
Next Steps
Dividend
What is Chembio Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate CEMI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CEMI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if CEMI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CEMI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CEMI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Chembio Diagnostics's salary, the management and board of directors tenure and is there insider trading?
2.9yrs
Average management tenure
CEO
John Sperzel (55yo)
5.6yrs
Tenure
US$1,456,097
Compensation
Mr. John J. Sperzel, III, B.Sc., has been the Chief Executive Officer and President of Chembio Diagnostics, Inc. since March 13, 2014. Mr. Sperzel is on leave of Absence on May 30, 2017. Mr. Sperzel served ...
CEO Compensation Analysis
Compensation vs. Market: John's total compensation ($USD1.46M) is about average for companies of similar size in the US market ($USD489.74K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
2.9yrs
Average Tenure
55yo
Average Age
Experienced Management: CEMI's management team is considered experienced (2.9 years average tenure).
Board Age and Tenure
2.3yrs
Average Tenure
63yo
Average Age
Experienced Board: CEMI's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Technology Officer Chief Science & Technology Officer and Executive VP |
| Shares | 30,000 |
| Max Price | US$7.41 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 20,000 |
| Max Price | US$5.81 |
| Entity | Individual |
| Role | Senior Key Executive Senior VP & Chief Commercial Officer |
| Shares | 15,000 |
| Max Price | US$6.75 |
Ownership Breakdown
Management Team
David Gyorke (59yo)
Senior VP & COO
- Tenure: 2.8yrs
John Sperzel (55yo)
President
- Tenure: 5.6yrs
- Compensation: US$1.46m
Javan Esfandiari (52yo)
Chief Science & Technology Officer and Executive VP
- Tenure: 15.8yrs
- Compensation: US$812.65k
Konstantin Lyashchenko
Research Director of Chembio Diagnostic Systems Inc
- Tenure: 0yrs
- Compensation: US$106.37k
Robert Passas (65yo)
Senior VP & Chief Commercial Officer
- Tenure: 3yrs
- Compensation: US$271.10k
Neil Goldman (51yo)
Executive VP & CFO
- Tenure: 1.8yrs
- Compensation: US$647.40k
Christine Rousseau
Vice President of Corporate Development
- Tenure: 1.3yrs
Board Members
Mary Polan (75yo)
Independent Director
- Tenure: 1.2yrs
- Compensation: US$207.58k
Gail Page (64yo)
Independent Director
- Tenure: 2.3yrs
- Compensation: US$25.00k
John Sperzel (55yo)
President
- Tenure: 5.6yrs
- Compensation: US$1.46m
John Potthoff (51yo)
Independent Director
- Tenure: 1.4yrs
- Compensation: US$167.55k
Kathy Davis (63yo)
Chair of the Board
- Tenure: 5.6yrs
- Compensation: US$75.00k
Company Information
Chembio Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Chembio Diagnostics, Inc.
- Ticker: CEMI
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$94.327m
- Shares outstanding: 17.57m
- Website: https://chembio.com
Number of Employees
Location
- Chembio Diagnostics, Inc.
- 555 Wireless Boulevard
- Hauppauge
- New York
- 11788
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CEMI | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Oct 2000 |
| D9IA | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Oct 2000 |
Biography
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers t ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/19 23:47 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.